Abstract
Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Current Drug Discovery Technologies
Title:Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Volume: 13 Issue: 1
Author(s): Vazhappilly C. George, Devanga R.N. Kumar and Rangasamy A. Kumar
Affiliation:
Keywords: Apoptosis, cell cycle arrest, DNA fragmentation, keratinocytes, melanoma, parthenolide.
Abstract: Background: Parthenolide (PN) has been reported to inhibit proliferation and induces apoptosis in a variety of cancer cells with different mechanisms. Nevertheless, to the best of our knowledge, its relative anticancer activity at lower doses has not been reported in HaCaT immortalized keratinocytes and A375 melanoma cells.
Objective and Method: The present study aimed to investigate the relative anticancer effects of PN by analysing its cytotoxicity, apoptosis and cell cycle arresting potentials in HaCaT and A375 cells.
Result: PN was found to be significantly cytotoxic with lower IC50 values of 1.45 µM and 2.9 µM (p<0.05) in HaCaT and A375 cells, respectively with nuclear disruption as evident by DAPI staining. A dose-dependent increase in DNA fragmentation indicated apoptotic cell death. Furthermore, the percentage of cells deposition at S (35.56 to 43.68%) and G0-G1 (27.15 to 56.44%) phases after 24 h of PN treatment, substantiate its cell cycle arresting potentials in HaCaT and A375 cells.
Conclusion: These comparative results provided substantial evidence to conclude the anticancer potential of PN, especially at lower dosages to induce cell death mechanisms in skin epidermal cells.
Export Options
About this article
Cite this article as:
George C. Vazhappilly, Kumar R.N. Devanga and Kumar A. Rangasamy, Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells, Current Drug Discovery Technologies 2016; 13 (1) . https://dx.doi.org/10.2174/1570163813666160224124029
DOI https://dx.doi.org/10.2174/1570163813666160224124029 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Biologically Active Natural Products of the Genus Callicarpa
Current Bioactive Compounds Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets LNA Antisense: A Review
Current Physical Chemistry Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Meet Our Editorial Board Member
Current Cancer Therapy Reviews Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Amyotrophic Lateral Sclerosis and Excitotoxicity: From Pathological Mechanism to Therapeutic Target
CNS & Neurological Disorders - Drug Targets CycloSal-dRFIB, a Thymidine Mimetic, Thymidine Kinase by-Pass Nucleoside Prodrug: Radioiodination, in vitro Cellular Uptake and Biodistribution in Murine Models
Current Radiopharmaceuticals Synthesis and <i>In Silico</i> Studies of C-4 Substituted Coumarin Analogues as Anticancer Agents
Current Computer-Aided Drug Design Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Current Drug Discovery Technologies The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target
Current Pharmaceutical Design